Tests liraglutide before embryo transfer in women with PCOS, obesity and infertility
Tests liraglutide before embryo transfer in obese women with PCOS and infertility.
Plain-language title generated from the registry record
Registry title: Liraglutide Treatment in Obese Infertile PCOS Women
Key facts
- Where
- Beijing, ChinaSee the 3 sites
- Phase
- Phase 4
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women with polycystic ovary syndrome (PCOS) and obesity who have infertility and have at least 1 frozen embryo ready for transfer.
- Age
- 20 to 40 years old.
- Sex
- Women only.
- Disease stage
- PCOS diagnosed by the Rotterdam criteria, with BMI from 25 kg/m2 to 35 kg/m2.
- Earlier treatment
- Must not have used any anti-diabetes or weight-loss medicines (metformin excluded) in the past 3 months. Must have at least 1 transplantable frozen embryo at the research center.
Main reasons for not taking part
- HbA1c of 9.0% (75 mmol/mol) or higher before enrollment
- Serious heart, digestive, liver or kidney disease, or chronic hepatitis B (HBsAg-positive), active tuberculosis or AIDS
- Past medullary thyroid cancer (or in the family), or past or current pancreatitis or acute cholecystitis
- Repeated failed implantations (3 or more) or 2 or more miscarriages, or past stillbirth
- Current smoker, alcohol or drug abuse
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 20 and 40 years old?
Source: NCT06742710, who can take part
Where in China
- Beijing Obstetrics and Gynecology HospitalBeijing, ChinaContact: Prof. YangNot yet recruiting
- Haidian District Maternal and Child Health Care HospitalBeijing, ChinaContact: Prof. LiuNot yet recruiting
- Peking University Third HospitalBeijing, ChinaContact: Ye LiuTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Peking University Third Hospital
- Trial code
- NCT06742710
- Record updated
- 29 May 2025
- Original description
Liraglutide, a hypoglycemic drug, can reduce weight and improve insulin resistance while stabilizing blood glucose metabolism without increasing the risk of hypoglycemia, and has been approved by the State Food and Drug Administration of China and the US Food and Drug Administration for the treatment of obesity. Polycystic ovary syndrome (PCOS) is the main cause of female anovulatory infertility, and it is also a high-risk group of obesity. Previous studies have suggested that liraglutide improves glucose metabolism, body weight, and inflammation levels in obese women with PCOS, and improves sex hormone profiles and menstrual cycles, possibly contributing to increased fertility.Read full original descriptionShow less
Liraglutide Treatment in Obese Infertile PCOS Women
Liraglutide, a hypoglycemic drug, can reduce weight and improve insulin resistance while stabilizing blood glucose metabolism without increasing the risk of hypoglycemia, and has been approved by the State Food and Drug Administration of China and the US Food and Drug Administration for the treatment of obesity. Polycystic ovary syndrome (PCOS) is the main cause of female anovulatory infertility, and it is also a high-risk group of obesity. Previous studies have suggested that liraglutide improves glucose metabolism, body weight, and inflammation levels in obese women with PCOS, and improves sex hormone profiles and menstrual cycles, possibly contributing to increased fertility.
Therefore, this project intends to test the following hypothesis through a large sample randomized controlled trial in obese and infertile PCOS women who are assisted by in vitro fertilization-frozen embryo transfer (IVF-FET), using liraglutide before transplantation to reduce weight can improve the live birth rate of assisted reproduction.
Inclusion: Women with polycystic ovary syndrome (PCOS) who meet the Rotterdam diagnostic criteria; Aged 20-40 years; 25 kg/m2 ≤ BMI ≤ 35 kg/m2; Have not used any anti-diabetes or weight-loss medications (metformin excluded) within the past 3 months; Have at least 1 transplantable frozen embryo available at the research center; Able to follow the study's contraceptive requirements.
Exclusion: Using drugs that affect appetite or nutrient absorption within the past 2 months (metformin excluded); Poor pregnancy and delivery history: recurrent failed implantations ≥3 times, spontaneous abortions ≥2 times; history of stillbirth, dystocia, or birth defects; previous pregnancies with preeclampsia, eclampsia, or HELLP syndrome; A contraindication or relative contraindication to using GLP-1 receptor agonists (history of medullary thyroid carcinoma or family history of medullary thyroid carcinoma, acute cholecystitis or pancreatitis in the acute phase or history of previous attacks, GLP-1 receptor agonist allergy, etc.); Current smokers, drug addicts, alcoholics, or individuals with substance abuse; Participants who have participated in any clinical trial within the past 3 months prior to screening; Diabetic ketoacidosis or other acute complications of diabetes; Uncontrolled hyperthyroidism or hypothyroidism, hypertension, systemic autoimmune diseases, etc. that may affect pregnancy and fetal development; Serious cardiovascular, digestive, liver, or kidney diseases, HBsAg-positive chronic hepatitis B, active pulmonary tuberculosis, or AIDS, etc. that are infectious or hereditary diseases; Any psychiatric or psychological disorders requiring drug treatment; Uncontrolled metabolic, autoimmune, or hereditary disease in the husband; Failure to comply with the contraceptive requirements of the study design; Failure to take medication regularly and follow up; Individuals with other conditions deemed unsuitable for participation in this clinical trial by the investigator; HbA1c ≥ 9.0% before enrollment; 17 hydroxyprogesterone in follicualr phase > 2.0 ng/ml.